Mesothelioma Medical

Resources for both patients and professionals searching 1000's of online resources every day

Menu

Resources > Mesothelioma Tests & Diagnosis > Clinical Trials > ALIMTA Plus Gemcitabine as Front-Line Chemotherapy

ALIMTA Plus Gemcitabine as Front-Line Chemotherapy

ALIMTA Plus Gemcitabine as Front-Line Chemotherapy for Patients with Malignant Pleural or Peritoneal Mesothelioma. A phase II Clinical Trial
Purpose:

ALIMTA Plus Gemcitabine as Front-Line Chemotherapy for Patients with Malignant Pleural or Peritoneal Mesothelioma. A phase II Clinical Trial.

Patient Inclusion:

	Histologically proven diagnosis of Malignant Pleural or Peritoneal Mesothelioma
	2 Weeks post pleurodesis
	Radiotherapy MUST BE completed at least 4 weeks
	Patient MUST have measurable disease
	At least 4 weeks must have elapsed and patients must have recovered from all side effects of Surgery

Exclusion Criteria:

	You are excluded from this trial if you have received prior chemotherapy for mesothelioma
	You are excluded from this trial if you have brain metastases.
	You are excluded from this trial if you have active infection
	You are excluded from this trial if you have pregnant or breast feeding.
	You are excluded from this trial if you have inability to take folic acid or vitamin B12 administration

Location/Contact Information:
Mary Hesdorffer, RN, BSN, Clinical Research Nurse
Columbia-Presbyterian Medical Center
Herbert Irving Comprehensive Cancer Center
Columbia University
161 Fort Washington Ave.
New York, NY 10032
Telephone: 212-305-1252
Fax: 212-305-6891
Email: mp317@columbia.edu

Get a Free Info Pack

Be sure to watch our mesothelioma video

First Name

Last Name

Address

City

State

Zip

Phone

Have you or a loved one
been diagnosed or have:

Mesothelioma:

Yes No

Symptoms of Mesothelioma:

Yes No

Lung Cancer:

Yes No

Fluid in the Lungs/ Pleural Effusion:

Yes No

Did you or your loved one work around asbestos

Yes No

Comment /
Info Request